Loading
A phase 3 trial of Fianlimab, Cemiplimab, Nivolumab in melanoma, run by Regeneron Pharmaceuticals, now recruiting.
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) is a phase 3 interventional study registered as NCT06246916 by Regeneron Pharmaceuticals, with 560 participants planned, started 2024-09-09 and due to reach its primary completion in 2027-03-22. Interventions recorded: fianlimab, cemiplimab, relatlimab+nivolumab. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Fianlimab, Regeneron, Cemiplimab, Melanoma.
Shares Fianlimab, Regeneron, Cemiplimab, Melanoma.
Shares Relatlimab + nivolumab, Advanced melanoma (unresectable stage III and stage IV), Nivolumab, Melanoma.
Shares Fianlimab, Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Fianlimab, Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Relatlimab + nivolumab, Nivolumab, Melanoma, Immune checkpoint inhibitors.
Shares Fianlimab, Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Melanoma, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/